What is Ovid Therapeutics Inc. (OVID) stock price today?

Ovid Therapeutics Inc. (OVID) is currently trading at $2.34, down 0.85% today.

What is OVID P/E ratio?

Ovid Therapeutics Inc.'s P/E ratio is -4.87. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is OVID return on equity (ROE)?

Ovid Therapeutics Inc.'s return on equity (ROE) is -23.64%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Ovid Therapeutics Inc.'s market cap?

Ovid Therapeutics Inc. has a market capitalization of $436.74M.

NCM · Biotechnology

Ovid Therapeutics Inc. (OVID) Stock

$2.34 -0.85% NCM: OVID Healthcare

Valuation

Metric	Value
Price	$2.34
Market Cap	$436.74M
P/E Ratio	-4.87
P/B Ratio	0.82
P/S Ratio	275.89
EPS (TTM)	$-0.47
52-Week High	$3.11
52-Week Low	$1.18
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-23.64%
ROA	-14.87%
ROCE	-26.29%
Gross Margin	-614.29%
Operating Margin	-600.00%
Net Margin	-339.33%
Debt/Equity	0.06
Current Ratio	11.25

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$208.0M	$2.0M	$0	$1.0M	$7.0M
Operating Profit	$124.0M	$-56.0M	$-59.0M	$-62.0M	$-42.0M
Net Profit	$123.0M	$-54.0M	$-52.0M	$-26.0M	$-17.0M
EPS	$1.76	$-0.77	$-0.74	$-0.37	$-0.24
Op Margin	59.6%	-3696.4%	-15122.7%	-10933.8%	-585.2%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$195.0M	$155.0M	$144.0M	$92.0M	$151.0M
Total Liabilities	$15.0M	$23.0M	$56.0M	$24.0M	$20.0M
Cash	$188.0M	$45.0M	$27.0M	$26.0M	$13.0M
Borrowings	$0	$17.0M	$16.0M	$15.0M	$13.0M

Latest News

Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer Insider Monkey · Jul 14, 2026 Ovid Therapeutics Names Kevin Norrett Chief Business Officer, Promotes CFO and Chief Strategy Officer MT Newswires · Jul 8, 2026 Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development GlobeNewswire · Jul 8, 2026 Ovid Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire · Jun 4, 2026 Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors GlobeNewswire · Jun 3, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$119.0M	$-55.0M	$-46.0M	$-56.0M	$-38.0M
Investing Cash Flow	$-2.0M	$-89.0M	$-3.0M	$55.0M	$-50.0M
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$118.0M	$-143.0M	$-18.0M	$-1.0M	$-13.0M
Free Cash Flow	$118.0M	$-57.0M	$-46.0M	$-56.0M	$-38.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.14
EV / EBITDA	-12.29
FCF Yield	-12.54%
Quick Ratio	12.39
Interest Coverage	0.00
Return 1Y	242.86%
Return 3Y	-32.96%
Return 5Y	-33.33%

Ownership

Insiders Held7.04%

Institutions Held64.43%

Institutions Float Held69.31%

Institutional Holder	Shares	Report Date
RA Capital Management, L.P.	10,714,000	2026-03-31
Janus Henderson Group PLC	10,714,000	2026-03-31
Affinity Asset Advisors, Llc	10,636,318	2026-03-31
Eventide Asset Management LLC	9,916,911	2026-03-31
Adage Capital Partners GP L.L.C.	6,163,781	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$340.42	+1.11%	38.93	$5.00T	0.32%
MSFTMicrosoft Corporation	$522.61	-1.35%	28.68	$3.88T	0.76%
GOOGLAlphabet Inc.	$348.29	-0.63%	16.94	$4.22T	0.26%
AMZNAmazon.com, Inc.	$254.06	-2.25%	19.82	$2.73T	0.00%
METAMeta Platforms, Inc.	$720.89	-0.06%	27.93	$1.84T	0.28%

About Ovid Therapeutics Inc.

Ovid Therapeutics Inc. is led by CEO Margaret Alexander, employs 23 people, headquartered in US, publicly traded since 2017.

Ovid Therapeutics Inc. (OVID) stock trades at $2.34 with a market capitalization of $436.74M. The stock is valued at a price-to-earnings (P/E) ratio of -4.87, price-to-book of 0.82, price-to-sales of 275.89. Over the past 52 weeks the stock has ranged between $1.18 and $3.11, and currently trades 24.8% below its 52-week high.

On profitability, Ovid Therapeutics Inc. generates a return on equity (ROE) of -23.64%, return on capital employed of -26.29%, an operating margin of -600.00%, a net profit margin of -339.33%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides